Organon and Samsung Bioepis' HADLIMA granted FDA interchangeability designation approval for all high- and-low concentration presentations.

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

The expanded interchangeability now applies to the 40mg prefilled syringe and the 40mg and 80mg autoinjectors, in addition to the 20mg and 80mg prefilled syringes. The Food and Drug Administration ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

Dosage for Humira (adalimumab) may vary based on the condition it’s being used to treat. Also, your doctor may adjust your dosage over the course of your treatment. Be sure to take the Humira ...

Non-infectious uveitis is a rare immune-mediated condition in children and is often treated with the tumor necrosis factor inhibitor adalimumab. Discontinuing the drug may be considered when ...

A new report released by the Michigan Health Purchasers Coalition suggests patients need to "shop around" to find the best ...

See full indications below. Patients treated with adalimumab products, including HADLIMA, are at increased risk for developing serious infections that may lead to hospitalization or death.

With this approval, YUFLYMA is now fully interchangeable with the reference product, Humira® (adalimumab), across all marketed dosage forms and strengths. YUFLYMA is a high-concentration ...